FMC CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
FMC Corporation received UK approval for Koban, a new herbicide with pethoxamid as the active ingredient, for use in oilseed rape. The company positions Koban as a residual partner product for weed control. This is FMC's third new herbicide active ingredient approved in the UK in recent years. Pethoxamid has existing regulatory history in Canada, the US, and the EU.
FMC Corporation submitted a regulatory dossier for rimisoxafen, a dual mode of action herbicide, to Brazilian authorities. The submission targets Brazil's large corn and soybean markets, aiming to address weed resistance. Rimisoxafen is the third novel herbicide FMC has advanced in Brazil, following Isoflex and Dodhylex. Regulatory approval is pending, with no current sales permitted.
FMC Corporation (NYSE: FMC) and AgroSpheres are advancing two RNA-based bioinsecticide candidates into global field trials in the U.S., Brazil, and Asia. The candidates target lepidopteran pests, which cause significant crop losses. The companies report that the bioinsecticides met or exceeded conventional chemistries in earlier tests. The trials aim to evaluate performance across various crops, climates, and pest pressures.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FMC (FMC CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent FMC coverage spans regulation, technology and earnings.
In the last 30 days, FMC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($16K). The most active reporter was Pfeiffer Nicholas, Corporate Controller, with 1 filing.
Approval may boost FMC's UK sales and market share in herbicides.
The filing signals progress toward product commercialization in Brazil, a major soy and corn market.
Positive but limited impact as the trials are early‑stage and revenue impact is uncertain.
Positive development indicating potential future revenue from novel bioinsecticide products.
The sizable stake could influence FMC's governance and market perception, potentially supporting the share price.
AlphAI scores every news story that mentions FMC with an AI model for sentiment and relevance, and aggregates insider trades from FMC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
FMC Corporation received UK approval for Koban, a new herbicide with pethoxamid as the active ingredient, for use in oilseed rape. The company positions Koban as a residual partner product for weed control. This is FMC's third new herbicide active ingredient approved in the UK in recent years. Pethoxamid has existing regulatory history in Canada, the US, and the EU.
2 min readFMC Corporation submitted a regulatory dossier for rimisoxafen, a dual mode of action herbicide, to Brazilian authorities. The submission targets Brazil's large corn and soybean markets, aiming to address weed resistance. Rimisoxafen is the third novel herbicide FMC has advanced in Brazil, following Isoflex and Dodhylex. Regulatory approval is pending, with no current sales permitted.
2 min readFMC Corporation (NYSE: FMC) and AgroSpheres are advancing two RNA-based bioinsecticide candidates into global field trials in the U.S., Brazil, and Asia. The candidates target lepidopteran pests, which cause significant crop losses. The companies report that the bioinsecticides met or exceeded conventional chemistries in earlier tests. The trials aim to evaluate performance across various crops, climates, and pest pressures.
2 min readAgroSpheres and FMC Corporation (FMC) announced two RNA-based bioinsecticide candidates entering global field trials across the U.S., Brazil, and Asia. The candidates target major lepidopteran pests causing $14B in annual crop losses. The collaboration aims to advance sustainable pest control solutions, with field trials marking a key milestone in their development.
2 min readFMC Corporation (FMC) announced Tessenderlo Group (TESB) completed a $403M minority equity investment, acquiring 20% of FMC's shares at $13.30 per share. Tessenderlo gains a board seat and faces a 3-year lock-up period. BofA and Goldman Sachs advised FMC.
2 min readFMC CORP (FMC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOR IMMEDIATE RELEASE FMC Corporation and Tessenderlo Group Complete Minority Equity Investment NEWS PROVIDED BY FMC Corporation → Sept. 23, 2026, 04:30 PM ET PHILADELPHIA, Sept. 23, 2026 /PRNewswire/ - FMC Corporation (NYSE: FMC), a leading global agricultural scien
2 min readFMC is reducing debt through asset sales and equity investments, aiming for $2.6B net debt by year-end. Analysts have lowered price targets, with 12 of 18 rating it 'Hold' or worse. FMC's dividend yield is 2.5%, but a cut is possible if turnaround plans fail. The stock trades at a forward P/E of 10.24x.
3 min readFMC Corp. held its Q2 2026 earnings call. It reported Q1 revenue of $762 million, down 4% year over year, and adjusted EBITDA of $72 million. Full-year guidance calls for revenue of $3.6 billion to $3.8 billion and adjusted EBITDA of $670 million to $730 million. The company targets $1 billion debt reduction in 2026 via an India business sale and other disposals.
6 min readFMC reported total revenue of $841.4 million for the quarter ended June 2026, down 19.9% year over year. Europe/Middle East/Africa generated $214.1 million (25.5%), below analysts’ $227.69 million. Latin America posted $277.9 million (33%), below $286.77 million. Asia revenue was $126.3 million (15%), above $98.78 million.
3 min readFMC Corporation reported Q2 2026 sales of $867.1M, down from $1,050.5M, and a net loss of $186.6M versus a $66.7M profit a year earlier. The company cut full-year 2026 revenue guidance to $3.50B to $3.70B. FMC kept its $0.08 quarterly dividend and cited cost and portfolio actions.
4 min read
